From the run-in period to week 48 , both treatments improved symptoms ( mean change -159 [ -194 to -125 ] in the as-needed beclometasone-formoterol group vs -144 [ -178 to -110 ] in the as-needed salbutamol group , difference -015 [ -060 to 030 ] ; p = 0507 ) , percentage of asthma control days ( 95 % [ 73 to 118 ] vs 109 % [ 87 to 131 ] , respectively , -14 [ -43 to 16 ] ; p = 0359 ) , use of reliever ( -029 [ -038 to -020 ] vs -027 [ -036 to -019 ] , respectively , -002 [ -013 to 010 ] ; p = 0794 ) , and lung function ( FEV1 , 0090 [ 0060 to 0120 ] vs 0090 [ 0060-0120 ] , respectively , 0001 [ -0040 to 0040 ] ; p = 0969 ) , and were well tolerated ( patients with serious adverse events , 32 [ 4 % ] and 41 [ 5 % ] , respectively ) .